FMP
Oyster Point Pharma, Inc.
OYST
NASDAQ
Inactive Equity
As of January 3, 2023, Oyster Point Pharma, Inc. was acquired by Viatris Inc. Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.
11.17 USD
0 (0%)
Dr. Jeffrey Nau
Healthcare
Biotechnology
NASDAQ
As of January 3, 2023, Oyster Point Pharma, Inc. was acquired by Viatris Inc. Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.
0001720725
US69242L1061
69242L106
202 Carnegie Ctr Ste 109
16093829032
US
303
Oct 31, 2019
Ms. Karen Castillo-Paff
Vice President of Communications & PR
0
N/A
Arty Ahmed
Vice President of Investor relations
0
N/A
Mr. Dave Benadon
Chief HR Officer
0
N/A
Ms. Loni Da Silva M.S.
Senior Vice President of Regulatory Affa...
0
N/A
Dr. Jeffrey Nau MMS, Ph.D.
Pres, Chief Executive Officer & Director
962.85k
1975
Mr. Daniel Lochner M.B.A.
Chief Financial Officer & Chief Bus. Off...
642k
1982
Mr. George Donato M.B.A.
Senior Vice President of CMC & Operation...
0
N/A
Mr. Barry Rosenfeld J.D.
Senior Vice President & Gen. Counsel
0
N/A
Dr. Eric Carlson Ph.D.
Chief Scientific Officer
0
N/A
Ms. Raegan A. McClain CCEP, J.D., L.L.M.
Chief Compliance & Privacy Officer
0
N/A
As of December 31, 2024, the total employee count stands at 303, with compensation values reflecting the last fiscal year ending on that date. Pay encompasses salary, bonuses, etc., All figures are in USD.